A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess Cardiovascular Outcomes Following Treatment with MK-3102 in Subjects with Type 2 Diabetes Mellitus
Read time: 1 mins
Last updated:29th Nov 2012
To assess the impact of MK-3102 25 mg q.w. on time to confirmed CV outcomes across the MK-3102 program To assess the safety and tolerability of MK-3102 25 mg q.w.
|Study start date||2012-11-29|